P
Presidio Pharmaceuticals
Discovers, develops and commercializes novel therapeutics for viral infections, including HCV and HIV
About Presidio Pharmaceuticals
Presidio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company established in 2006, with its headquarters in San Francisco, California. The company was founded by Omar Haffar, who also served as President and CEO. From its inception, Presidio focused on developing small-molecule antiviral therapeutics. Initially targeting the HIV market, the company shifted its primary focus to the underserved Hepatitis C virus (HCV) market, which demonstrated significant funding potential.
The company's business model centers on the discovery, development, and subsequent licensing of its drug candidates. Presidio strategically forms partnerships and out-licensing agreements for its programs. This is evident in its collaborations with companies like Boehringer Ingelheim for clinical trials and licensing agreements with Pharco Pharmaceuticals for distribution in Egypt and the MENA region, and Ascletis for the Chinese market. A significant milestone was the 2016 licensing of its lead compound, ravidasvir, to the Drugs for Neglected Diseases initiative (DNDi) for use in low- and middle-income countries.
Presidio's lead product is ravidasvir (formerly PPI-668), a potent, pan-genotypic NS5A inhibitor for treating HCV. The drug is designed for convenient once-daily oral dosing and can be used in combination with other antiviral classes to combat resistance. Clinical trials for ravidasvir, particularly in combination with sofosbuvir, have shown high efficacy, with a 97% cure rate for Hepatitis C patients. These successful trials led to the treatment receiving conditional registration in Malaysia in 2021, full approval in 2024, and its inclusion in the WHO's Essential Medicines List in 2023.
Financially, Presidio has navigated several funding rounds to support its clinical programs. The company raised a total of $91.9 million over seven rounds, including a notable $26 million Series B in August 2007 and a $21.8 million Series C in June 2014. Its investor syndicate includes prominent venture capital firms such as New Leaf Venture Partners, Panorama Capital, Bay City Capital, and Baker Brothers Investments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Infections and Infectious Diseases, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2014 | $22M | $87M | Undisclosed | — |
| EARLY VCOther financing | Oct 2012 | $8M | $32M | Undisclosed | — |
Growth signals
Latest recorded traffic for Presidio Pharmaceuticals is 910 monthly website visits, up 30% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Presidio Pharmaceuticals in the San Francisco ecosystem
The Presidio Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Panorama Capital
Ventures West- BCBay City Capital
- NPNexus Medical Partners
Series B and later1 investor entered at this stage
New Leaf Venture Partners
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Presidio Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Presidio Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









